LongTermGevity (LTG)'s lead invention is a first-in-class and first-to-market non-opioid, non-addictive topical pain medicine that targets pain modulation through serotonin pathways in the peripheral nervous system. LongTermGevity is uniquely positioned to execute its first-in-human trials and establish a new standard of care for chronic pain through safe, effective, and non-addictive therapeutics.